دورية أكاديمية
أعرض في EDS

The Ratio of CD226 and TIGIT Expression in Tfh and PD-1 + ICOS + Tfh Cells Are Potential Biomarkers for Chronic Antibody-Mediated Rejection in Kidney Transplantation.

التفاصيل البيبلوغرافية
العنوان: The Ratio of CD226 and TIGIT Expression in Tfh and PD-1 + ICOS + Tfh Cells Are Potential Biomarkers for Chronic Antibody-Mediated Rejection in Kidney Transplantation.
المؤلفون: Fan JW; Department of Laboratory Medicine, West China Hospital, Sichuan University, Chengdu 610041, China., Fan Y; Department of Urology, National Clinical Research Center for Geriatrics and Organ Transplantation Center, West China Hospital of Sichuan University, No. 37 Guoxue Xiang, Chengdu 610041, China.; Department of Urology, West China School of Nursing, Sichuan University, No. 37 Guoxue Xiang, Chengdu 610041, China., Wan ZL; Department of Laboratory Medicine, West China Hospital, Sichuan University, Chengdu 610041, China., Yan L; Department of Laboratory Medicine, West China Hospital, Sichuan University, Chengdu 610041, China., Li YM; Department of Laboratory Medicine, West China Hospital, Sichuan University, Chengdu 610041, China., Bai YJ; Department of Laboratory Medicine, West China Hospital, Sichuan University, Chengdu 610041, China., Wang LL; Department of Laboratory Medicine, West China Hospital, Sichuan University, Chengdu 610041, China., Chen J; Department of Laboratory Medicine, West China Hospital, Sichuan University, Chengdu 610041, China., Li Y; Department of Laboratory Medicine, West China Hospital, Sichuan University, Chengdu 610041, China.
المصدر: Journal of immunology research [J Immunol Res] 2022 Jun 12; Vol. 2022, pp. 5326083. Date of Electronic Publication: 2022 Jun 12 (Print Publication: 2022).
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Hindawi Publishing Corporation Country of Publication: Egypt NLM ID: 101627166 Publication Model: eCollection Cited Medium: Internet ISSN: 2314-7156 (Electronic) Linking ISSN: 23147156 NLM ISO Abbreviation: J Immunol Res Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Cairo, Egypt : Hindawi Publishing Corporation, [2014]-
مواضيع طبية MeSH: Glomerulonephritis, IGA* , Graft Rejection* , Graft vs Host Disease*/etiology , Kidney Transplantation*/adverse effects, Antibodies ; Antigens, Differentiation, T-Lymphocyte/metabolism ; Biomarkers/metabolism ; Humans ; Inducible T-Cell Co-Stimulator Protein/metabolism ; Programmed Cell Death 1 Receptor/metabolism ; Receptors, Immunologic ; T Follicular Helper Cells
مستخلص: Kidney transplantation is the ideal treatment for end-stage renal disease (ESRD). Chronic antibody-mediated rejection (CAMR) is the main cause of graft failure. Tfh and B cells are key immune cells that play important roles in CAMR. In this study, the populations of different Tfh cell phenotypes and B cell subsets in CAMR were investigated in a total of 36 patients. Based on Banff-2019, 15 patients were diagnosed with CAMR (CAMR group), 11 recipients were diagnosed with recurrent or de novo IgA nephropathy (IgAN group), and 10 patients displayed stable renal function (stable group). The Tfh and B cell subsets were analyzed by flow cytometry. The percentage and absolute number of PD-1 + ICOS + Tfh cells were significantly higher in CAMR ( p < 0.05), as was the ratio of CD226 + Tfh cells to TIGIT + Tfh cells ( p < 0.05). Compared with stable recipients, CAMR patients had lower naïve B cells and higher unswitched memory B cells, which were also significantly related to renal function ( p < 0.05). Using the logistic regression model, we concluded that the estimated glomerular filtration rate (eGFR), absolute number of PD-1 + ICOS + Tfh cells, and ratio of CD226 + Tfh cells to TIGIT + Tfh cells were independent risk factors for CAMR. The combination of eGFR, PD-1 + ICOS + Tfh cells, and the ratio of CD226 + Tfh cells to TIGIT + Tfh cells showed better diagnostic efficacy for CAMR than each single parameter. The collective findings show that monitoring different Tfh phenotypes and B cell subsets is beneficial to kidney transplant recipients and implicate the combination of eGFR, number of PD-1 + ICOS + Tfh cells, and ratio of CD226 + Tfh cells to TIGIT + Tfh cells as a biomarker for diagnosing CAMR. The findings may also inform new strategies to identify and treat CAMR.
Competing Interests: The authors declare no conflicts of interest regarding the publication of this paper.
(Copyright © 2022 Ji-wen Fan et al.)
References: Front Immunol. 2021 Apr 14;12:651357. (PMID: 33936071)
Haematologica. 2015 Nov;100(11):1415-25. (PMID: 26250578)
Transplantation. 2020 Feb;104(2):e46-e56. (PMID: 32000235)
Nat Immunol. 2009 Jan;10(1):48-57. (PMID: 19011627)
J Cell Mol Med. 2020 Dec;24(24):14270-14279. (PMID: 33145962)
Cancer Immunol Immunother. 2018 Nov;67(11):1659-1667. (PMID: 30232519)
Front Immunol. 2022 Feb 22;13:840457. (PMID: 35273617)
Transplantation. 2016 Aug;100(8):1650-5. (PMID: 27362303)
Nat Rev Immunol. 2015 Mar;15(3):137-48. (PMID: 25656706)
Diagnostics (Basel). 2021 Apr 01;11(4):. (PMID: 33916199)
Cancer Rep (Hoboken). 2019 Aug;2(4):e1160. (PMID: 32721130)
Transpl Int. 2020 Jan;33(1):30-40. (PMID: 31705678)
Am J Transplant. 2021 Feb;21 Suppl 2:21-137. (PMID: 33595191)
Front Immunol. 2016 Oct 21;7:432. (PMID: 27818660)
J Exp Med. 2003 Aug 18;198(4):557-67. (PMID: 12913096)
Transpl Immunol. 2021 Dec;69:101459. (PMID: 34461243)
BMC Immunol. 2019 Aug 5;20(1):26. (PMID: 31382877)
Am J Transplant. 2021 Jul;21(7):2413-2423. (PMID: 33382185)
J Am Soc Nephrol. 2020 Oct;31(10):2457-2474. (PMID: 32723838)
Annu Rev Immunol. 2011;29:621-63. (PMID: 21314428)
Immunity. 2009 Mar 20;30(3):324-35. (PMID: 19303387)
Biochim Biophys Acta Mol Basis Dis. 2018 Sep;1864(9 Pt B):3085-3098. (PMID: 29960041)
Clin Exp Immunol. 2015 May;180(2):329-40. (PMID: 25557528)
Am J Transplant. 2020 Jan;20(1):75-87. (PMID: 31250973)
Front Immunol. 2021 Apr 30;12:656846. (PMID: 33995373)
Trends Immunol. 2017 Jan;38(1):20-28. (PMID: 27793572)
Transplant Rev (Orlando). 2015 Apr;29(2):45-52. (PMID: 25867605)
Am J Transplant. 2017 Jun;17(6):1490-1501. (PMID: 27888555)
Front Cell Dev Biol. 2020 Jul 24;8:564. (PMID: 32850777)
Pharmaceuticals (Basel). 2021 Feb 28;14(3):. (PMID: 33670993)
J Am Soc Nephrol. 2016 Nov;27(11):3299-3307. (PMID: 27020853)
Nat Commun. 2017 Oct 10;8(1):847. (PMID: 29018187)
Front Immunol. 2019 Sep 10;10:2071. (PMID: 31552030)
J Am Soc Nephrol. 2006 Oct;17(10):2937-44. (PMID: 16988059)
Transplantation. 2020 May;104(5):911-922. (PMID: 31895348)
PLoS One. 2016 Feb 03;11(2):e0147951. (PMID: 26840537)
Front Immunol. 2020 Aug 21;11:1883. (PMID: 32983109)
J Immunol. 2018 Jan 1;200(1):336-346. (PMID: 29180490)
المشرفين على المادة: 0 (Antibodies)
0 (Antigens, Differentiation, T-Lymphocyte)
0 (Biomarkers)
0 (CD226 antigen)
0 (ICOS protein, human)
0 (Inducible T-Cell Co-Stimulator Protein)
0 (Programmed Cell Death 1 Receptor)
0 (Receptors, Immunologic)
0 (TIGIT protein, human)
تواريخ الأحداث: Date Created: 20220623 Date Completed: 20220624 Latest Revision: 20220716
رمز التحديث: 20231215
مُعرف محوري في PubMed: PMC9206998
DOI: 10.1155/2022/5326083
PMID: 35733922
قاعدة البيانات: MEDLINE
الوصف
تدمد:2314-7156
DOI:10.1155/2022/5326083